培美曲塞单药一线治疗老年晚期肺腺癌近期疗效分析 |
| |
引用本文: | 李君东,唐淑红,任晓安.培美曲塞单药一线治疗老年晚期肺腺癌近期疗效分析[J].中国当代医药,2011,18(15):17-18. |
| |
作者姓名: | 李君东 唐淑红 任晓安 |
| |
作者单位: | 大连市第五人民医院肿瘤内科,辽宁,大连,116021 |
| |
摘 要: | 目的:观察培美曲赛单药一线治疗25例老年(〉70岁)晚期肺腺癌患者的近期疗效及毒性反应。方法:收集本院2008年8月~2009年12月25例经病理组织学和(或)细胞学检查确诊的肺腺癌患者,男8例,女17例,中位年龄74岁(范围71~78岁),化疗方案为培美曲赛500mg/m2第1天,每3周重复。对接受2个或2个以上化疗周期的患者进行疗效及毒副反应评价。结果:近期疗效评价采用RECIST1.0标准,毒副反应评价按照WHO毒性评定标准。其中完全缓解(CR)0例,部分缓解(PR)8例,稳定(SD)10例,进展(PD)7例,总有效率为(CR+PR)32%,临床获益率为(CR+PR+SD)72%,1年生存率为36%。毒副反应主要为骨髓抑制及胃肠道反应,经短期对症处理后不影响下一周期化疗。结论:培美曲赛一线治疗老年晚期肺腺癌有较好临床获益率,毒副反应轻,老年患者易于耐受。
|
关 键 词: | 培美曲赛 肺腺癌 老年患者 一线治疗 |
Clinical observation of pemetrexed in treating advanced adenocarcinoma of lung of elderly patients |
| |
Authors: | LI Jundong TANG Shuhong REN xiaoan |
| |
Institution: | Department of Oncology, the Fifth People′s Hospital of Dalian, Liaoning Province, Dalian 116021, China |
| |
Abstract: | Objective:To evaluate the clinical effect and toxicity of pemetrexed in first line of treating advanced adenocarcinoma of lung in elderly patients (70 years). Methods:Totally 25 patients collected from our hospital between Aug. 2008 and Dec. 2009 were enrolled into the study, with adenocarcinoma of lung diagnosed by pathology or cytology. 8 were men, 17 were women, the median age was 74 years (from 71 to 78 years). The patients received pemetrexed at a dose of 500 mg/m2, the chemotherapy was repeated every 21 days on two cycles at least. Results:Among 25 patients, 8 got PR, 10 were SD and 7 were PD, the overall response rate (CR+PR) was 32%, the clinical benefit rate (CR+PR+SD) was 72%, 1 year survival rate was 36%. The main side effects were inhibition of bone marrow and gastrointestinal reaction, but were tolerable. Conclusion:The regimen of pemetrexed has well clinical benefit rate, slight adverse reaction. It can be tolerant by elderly patients. |
| |
Keywords: | Pemetrexed Advanced adenocarcinoma of lung Elderly patients First-line treatment |
本文献已被 CNKI 维普 万方数据 等数据库收录! |
|